Cited by 187Immunotherapy and Immune ResponsesRNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination

Open access

Persano, Stefano, Guevara, Maria L., Li, Zhaoqi, Mai, Junhua, Ferrari, Mauro, Pompa, Pier Paolo, Shen, Haifa·2017·Biomaterials

DOI 10.1016/j.biomaterials.2017.02.019PMC PMC5378555

Open this paper in CoChat — free account

Abstract

mRNA-based vaccines have the benefit of triggering robust anti-cancer immunity without the potential danger of genome integration from DNA vaccines or the limitation of antigen selection from peptide vaccines. Yet, a conventional mRNA vaccine comprising of condensed mRNA molecules in a positively charged protein core structure is not effectively internalized by the antigen-presenting cells. It cannot offer sufficient protection for mRNA molecules from degradation by plasma and tissue enzymes either. Here, we have developed a lipopolyplex mRNA vaccine that consists of a poly-(β-amino ester) polymer mRNA core encapsulated into a 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine/1,2-dioleoyl-sn-glycero-3-phosphatidyl-ethanolamine/1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000 (EDOPC/DOPE/DSPE-PEG) lipid shell. This core-shell structured mRNA vaccine enters dendritic cells through macropinocytosis. It displayed intrinsic adjuvant activity by potently stimulating interferon-β and interleukin-12 expression in dendritic cells through Toll-like receptor 7/8 signaling. Dendritic cells treated with the mRNA vaccine displayed enhanced antigen presentation capability. Mice bearing lung metastatic B16-OVA tumors expressing the ovalbumin antigen were treated with the lipopolyplex mRNA, and over 90% reduction of tumor nodules was observed. Collectively, this core-shell structure offers a promising platform for mRNA vaccine development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.biomaterials.2017.02.019

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,496
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVO
Trombetta, E. S., & Mellman, I. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104538 · Cited by 1,226
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J. S., Gailani, F., Riley, L. B., Conlon, K. C., Pockaj, B. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 935

Show all 43 references

Research works printed but not linked: 1

Fotin-Mleczek, 2011, Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity, J. Immunother. (Hagerstown, Md 1997), 34, 1

Sorted by citations

Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA vaccine for cancer immunotherapy
Miao, L., Zhang, Y., & Huang, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01335-5 · Cited by 966
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 649
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
Lorentzen, C. L., Haanen, J. B. A. G., Met, Ö., & Svane, I. M. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00372-2 · Cited by 555
Algorithm for optimized mRNA design improves stability and immunogenicity
Zhang, H., Zhang, L., Lin, A., Xu, C., Li, Z., Liu, K., Liu, B., Ma, X., Zhao, F., Jiang, H., et al. (2023) · Nature · doi:10.1038/s41586-023-06127-z · Cited by 531
Self-citation
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Liu, M. A. (2019) · Vaccines · doi:10.3390/vaccines7020037 · Cited by 442
Nucleic acid delivery for therapeutic applications
Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 351
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy
Guevara, M. L., Persano, F., & Persano, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.589959 · Cited by 261
Self-citation
Formulation and Delivery Technologies for mRNA Vaccines
Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 228
Non-viral COVID-19 vaccine delivery systems
Park, K. S., Sun, X., Aikins, M. E., & Moon, J. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.008 · Cited by 216
Biomaterials for vaccine-based cancer immunotherapy
Zhang, R., Billingsley, M. M., & Mitchell, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.008 · Cited by 204
Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities
Karlsson, J. E., Rhodes, K. R., Green, J. J., & Tzeng, S. Y. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1796628 · Cited by 196
Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation
Coolen, A.-L., Lacroix, C., Mercier‐Gouy, P., Delaune, E. A., Monge, C., Exposito, J., & Verrier, B. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.019 · Cited by 198
Chemical Strategies to Boost Cancer Vaccines
Li, W., & Li, Y. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00833 · Cited by 175
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F. H., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 190
Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity
Mai, Y., Guo, J., Zhao, Y., Ma, S., Hou, Y., & Yang, J. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104143 · Cited by 163
Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
Cagigi, A., & Loré, K. (2021) · Vaccines · doi:10.3390/vaccines9010061 · Cited by 153
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity
Yang, R., Deng, Y., Huang, B., Huang, L., Lin, A., Li, Y., Wang, W., Liu, J., Lu, S., Zhan, Z., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00634-z · Cited by 130
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130
Self-citation
The roles of polymers in mRNA delivery
Huang, P., Deng, H., Zhou, Y., & Chen, X. S. (2022) · Matter · doi:10.1016/j.matt.2022.03.006 · Cited by 131
From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Zhou, F., Huang, L., Li, S., Yang, W., Chen, F., Cai, Z., Liu, X., Xu, W., Lehto, V., Lächelt, U., et al. (2023) · Exploration · doi:10.1002/exp.20210146 · Cited by 117
mRNA vaccines for COVID-19 and diverse diseases
Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M. F., He, H., Chang, J. K., Liang, X., Weng, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.032 · Cited by 121
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 124
Poly(β-amino ester)-based gene delivery systems: From discovery to therapeutic applications
Cordeiro, R. A., Serra, A. C., Coelho, J. F. J., & Faneca, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.024 · Cited by 107
mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 111
Recent developments of RNA-based vaccines in cancer immunotherapy
Faghfuri, E., Pourfarzi, F., Faghfouri, A. H., Shadbad, M. A., Hajiasgharzadeh, K., & Baradaran, B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1815704 · Cited by 100
Recent progress of graphene oxide as a potential vaccine carrier and adjuvant
Cao, W., He, L., Cao, W., Huang, X., Jia, K., & Dai, J. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.06.009 · Cited by 95
mRNA Polyplexes with Post-Conjugated GALA Peptides Efficiently Target, Transfect, and Activate Antigen Presenting Cells
Lou, B., Koker, S. D., Lau, C. Y. J., Hennink, W. E., & Mastrobattista, E. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00524 · Cited by 92
Adjuvant physiochemistry and advanced nanotechnology for vaccine development
Ren, H., Jia, W., Xie, Y., Yu, M., & Chen, Y. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00848c · Cited by 91
Cell-Penetrating Peptides: Emerging Tools for mRNA Delivery
Yokoo, H., Oba, M., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010078 · Cited by 88
Room temperature synthesis of dendritic mesoporous silica nanoparticles with small sizes and enhanced mRNA delivery performance
Wang, Y., Song, H., Yu, M., Xu, C., Liu, Y., Tang, J., Yang, Y., & Yu, C. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00544c · Cited by 85
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 104
Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells
Yong, S., Chung, J. Y., Song, Y., Kim, J., Ra, S., & Kim, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119401 · Cited by 81
Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines
Alfagih, I. M., Aldosari, B. N., AlQuadeib, B. T., Almurshedi, A. S., & Alfagih, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010045 · Cited by 80
Advances in the polymeric delivery of nucleic acid vaccines
Chen, G., Zhao, B., Ruiz, E. F., & Zhang, F. (2022) · Theranostics · doi:10.7150/thno.70853 · Cited by 76
Recent advances in applying nanotechnologies for cancer immunotherapy
Mahjub, R., Jatana, S., Lee, S. E., Qin, Z., Pauli, G., Soleimani, M., Madadi, S., & Li, S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.010 · Cited by 76
Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy
Lee, D., Huntoon, K. M., Wang, Y., Jiang, W., & Kim, B. Y. S. (2021) · Advanced Materials · doi:10.1002/adma.202007576 · Cited by 74
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 76
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 74
Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines
Rinoldi, C., Zargarian, S. S., Nakielski, P., Li, X., Liguori, A., Petronella, F., Presutti, D., Wang, Q., Costantini, M., Sio, L. D., et al. (2021) · Small Methods · doi:10.1002/smtd.202100402 · Cited by 78
Recent advances in mRNA vaccine delivery
Tan, L., & Sun, X. (2018) · Nano Research · doi:10.1007/s12274-018-2091-z · Cited by 71
Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy
Hao, Y., Ji, Z., Zhou, H., Wu, D., Gu, Z., Wang, D., & ten Dijke, P. (2023) · MedComm · doi:10.1002/mco2.339 · Cited by 71
At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids
Uludağ, H., Ubeda, A., & Ansari, A. S. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00131 · Cited by 67
Serum Nuclease Susceptibility of mRNA Cargo in Condensed Polyplexes
Yen, A., Cheng, Y., Sylvestre, M., Gustafson, H. H., Puri, S., & Pun, S. H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00134 · Cited by 69
Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
Fan, T., Xu, C., Wu, J., Cai, Y., Cao, W., Shen, H., Zhang, M., Zhu, H., Yang, J., Zhu, Z., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn9961 · Cited by 62
Self-citation
Optimization of the Linker Length of Mannose-Cholesterol Conjugates for Enhanced mRNA Delivery to Dendritic Cells by Liposomes
Wang, F., Xiao, W., Elbahnasawy, M. A., Bao, X., Zheng, Q., Gong, L., Zhou, Y., Yang, S., Fang, A., Farag, M. M. S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00980 · Cited by 59
Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
Yang, Y., Li, H., Fotopoulou, C., Cunnea, P., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049340 · Cited by 61
Codelivery of mRNA with α-Galactosylceramide Using a New Lipopolyplex Formulation Induces a Strong Antitumor Response upon Intravenous Administration
Guevara, M. L., Jilesen, Z., Stojdl, D., & Persano, S. (2019) · ACS Omega · doi:10.1021/acsomega.9b00489 · Cited by 58
Self-citation
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57
Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy
Zhang, X., Men, K., Zhang, Y., Zhang, R., Yang, L., & Duan, X. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s198747 · Cited by 57
Poly(β-amino ester)s-based nanovehicles: Structural regulation and gene delivery
Zhang, J., Cai, X., Dou, R., Guo, C., Tang, J., Hu, Y., Chen, H.-Q., & Chen, J. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.019 · Cited by 59
Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
Guevara, M. L., Persano, S., & Persano, F. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190619150221 · Cited by 57
Self-citation
Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine
Perche, F., Clemençon, R., Schulze, K., Ebensen, T., Guzmán, C. A., & Pichon, C. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.07.014 · Cited by 55
Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens
Poveda, C., Biter, A. B., Bottazzi, M. E., & Strych, U. (2019) · Vaccines · doi:10.3390/vaccines7040131 · Cited by 54
Recent advancements in lipid–mRNA nanoparticles as a treatment option for cancer immunotherapy
Karmacharya, P., Patil, B. R., & Kim, J. O. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00569-9 · Cited by 54
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55
Edible and cation-free kiwi fruit derived vesicles mediated EGFR-targeted siRNA delivery to inhibit multidrug resistant lung cancer
Huang, H., Yi, X., Wei, Q., Li, M., Cai, X., Lv, Y., Weng, L., Mao, Y., Fan, W., Zhao, M., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01766-w · Cited by 53
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
Han, G., Noh, D., Lee, H., Lee, S., Kim, S., Yoon, H. Y., & Hyeon, L. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114973 · Cited by 53
Emerging Concepts of Nanobiotechnology in mRNA Delivery
Wang, Y., & Yu, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202003545 · Cited by 54
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
Scaffold-mediated delivery for non-viral mRNA vaccines
Chen, R., Zhang, H., Yan, J., & Bryers, J. D. (2018) · Gene Therapy · doi:10.1038/s41434-018-0040-9 · Cited by 50
Advances in the design and delivery of RNA vaccines for infectious diseases
Lokras, A. G., Bobak, T. R., Baghel, S. S., Sebastiani, F., & Foged, C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115419 · Cited by 52
mRNA delivery in cancer immunotherapy
Zhong, Y., Du, S., & Dong, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.001 · Cited by 49
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 43
Immunostimulation and Immunosuppression: Nanotechnology on the Brink
Fontana, F., Figueiredo, P., Bauleth‐Ramos, T., Correia, A., & Santos, H. A. (2018) · Small Methods · doi:10.1002/smtd.201700347 · Cited by 41
An mRNA vaccine elicits STING-dependent antitumor immune responses
Chen, Z., Meng, C., Mai, J., Liu, Y., Li, H., & Shen, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.013 · Cited by 41
Self-citation
Survival strategies of cancer cells: the role of macropinocytosis in nutrient acquisition, metabolic reprogramming, and therapeutic targeting
Xu, G., Zhang, Q., Cheng, R., Qu, J., & Li, W. (2025) · Autophagy · doi:10.1080/15548627.2025.2452149 · Cited by 41
Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells
Shen, H., Sun, T., Hoang, H. H., Burchfield, J. S., Hamilton, G. F., Mittendorf, E. A., & Mauro Ferrari, B. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.002 · Cited by 37
Self-citation
Non-Viral Carriers for Nucleic Acids Delivery: Fundamentals and Current Applications
Shtykalova, S., Deviatkin, D., Freund, S., Egorova, A., & Kiselev, A. (2023) · Life · doi:10.3390/life13040903 · Cited by 43
Nanoliposomes as safe and efficient drug delivery nanovesicles
Fatfat, Z., Karam, M., Maatouk, B. I., Fahs, D., & Gali‐Muhtasib, H. U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91668-4.00002-2 · Cited by 33
Emerging advances in delivery systems for mRNA cancer vaccines
Jiang, Z., Xu, Y., Du, G., & Sun, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.039 · Cited by 35
Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination
Zhang, W., Liu, Y., Chin, J. M., & Phua, K. K. L. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.011 · Cited by 33
Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination
Sun, X., Zeng, L., & Huang, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3089 · Cited by 34
Single Micelle Vectors based on Lipid/Block Copolymer Compositions as mRNA Formulations for Efficient Cancer Immunogene Therapy
Li, J., Men, K., Gao, Y., Wu, J., Lei, S., Yang, Y., & Pan, H. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00461 · Cited by 30
Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery
Sunoqrot, S., Gaber, S. A. A., Abujaber, R., Al-Majawleh, M., & Talhouni, S. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00843 · Cited by 32
Nucleic acid-loaded poly(beta-aminoester) nanoparticles for cancer nano-immuno therapeutics: the good, the bad, and the future
Magaña, J. R., Guerra‐Rebollo, M., Borrós, S., & Fornaguera, C. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01585-y · Cited by 28
Emerging Advances in Cationic Liposomal Cancer Nanovaccines: Opportunities and Challenges
Ahmad, M. Z., Ahmad, J., Alasmary, M. Y., Abdel‐Wahab, B. A., Warsi, M. H., Haque, A., & Chaubey, P. (2021) · Immunotherapy · doi:10.2217/imt-2020-0258 · Cited by 29
A single immunization with core–shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs
Wan, J., Yang, J., Wang, Z., Shen, R., Zhang, C., Wu, Y., Zhou, M., Chen, H., Fu, Z. F., Sun, H., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2270081 · Cited by 29
Self-citation
Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines
Lin, F., Lin, E. Z., Anekoji, M., Ichim, T. E., Hu, J. K., Marincola, F. M., Jones, L. D., Kesari, S., & Ashili, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04724-0 · Cited by 28
Harnessing the layer-by-layer assembly technique to design biomaterials vaccines for immune modulation in translational applications
Tang, T., Weng, T., Jia, H., Luo, S., Xu, Y., Li, L., & Zhang, P. (2019) · Biomaterials Science · doi:10.1039/c8bm01219a · Cited by 28
Poly (beta‐amino ester) as an in vivo nanocarrier for therapeutic nucleic acids
Nezhad, M. S. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28269 · Cited by 28
Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
Zhang, X., Wang, X., Hou, L., Xu, Z. Q., Liu, Y., & Wang, X. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1130937 · Cited by 28
Carboxymethylated Alginate-Resiquimod Micelles Reverse the Immunosuppressive Tumor Microenvironment and Synergistically Enhance the Chemotherapy and Immunotherapy for Gastric Cancer
Chen, J., Liu, X., Zhao, S., Chen, H., Lu, T., Wang, J., Han, J., Wu, W., Shen, X., & Li, C. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c06828 · Cited by 28
Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy
Neill, B., Romero, A. R., & Fenton, O. S. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00721 · Cited by 31
Advances in mRNA vaccines
Li, M., Wang, Z., Xie, C., & Xia, X. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.011 · Cited by 30
Non‐viral gene delivery for cancer immunotherapy
Wang, W., Saeed, M., Zhou, Y., Yang, L., Wang, D., & Yu, H. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3092 · Cited by 29
Advancing mRNA technologies for therapies and vaccines: An African context
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25
Nanotechnology in the arena of cancer immunotherapy
Asadujjaman, M., Cho, K. H., Jang, D.-J., Kim, J.-E., & Jee, J. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01207-4 · Cited by 27
Advancing mRNA vaccines: A comprehensive review of design, delivery, and efficacy in infectious diseases
Lu, Y., Qian, C., Huang, Y., Ren, T., Xie, W., Xia, N., & Li, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145501 · Cited by 28
Smart CAR-T Nanosymbionts: archetypes and proto-models
Baena, J. C., Victoria, J. S., Toro-Pedroza, A., Aragón, C. C., Ortiz‐Guzman, J., García-Robledo, J. E., Torres, D., Ríos-Serna, L. J., Albornóz, L. L., Rosales, J. D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635159 · Cited by 27
In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
Esteban, I., Pastor-Quiñones, C., Usero, L., Plana, M., García, F., & Leal, L. (2021) · Viruses · doi:10.3390/v13030501 · Cited by 26
Biomaterials for polynucleotide delivery to anchorage-independent cells
Ansari, A. S., Santerre, P., & Uludağ, H. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01833a · Cited by 23
Biomimetic functionalized metal organic frameworks as multifunctional agents: Paving the way for cancer vaccine advances
Tousian, B., Khosravi, A., Ghasemi, M. H., & Kadkhodaie, M. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101134 · Cited by 24

Authors: Persano, S., Guevara, M. L., Li, Z., Mai, J., Ferrari, M., Pompa, P. P., & Shen, H.
Affiliations: Houston Methodist (US)
Italian Institute of Technology (IT)
Corresponding author: Shen, Haifa
ORCID: Persano, Stefano
Mai, Junhua
Pompa, Pier Paolo
Shen, Haifa
Venue: Biomaterials
Publisher: Elsevier BV
Published: 2017-05
Volume: 125
Pages: 81-89
ISSN: 0142-9612 (ISSN-L)
DOI: 10.1016/j.biomaterials.2017.02.019
PMC: PMC5378555
OpenAlex: W2589539207
Cited by: 187
References: 43
Citations by year: 2026: 10 · 2025: 26 · 2024: 30 · 2023: 28 · 2022: 26 · 2021: 18 · 2020: 20 · 2019: 13 · 2018: 12 · 2017: 4
FWCI: 6.06
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (am, 296 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Biomaterials (acceptedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (1R01CA193880-01A1, U54CA210181)
U.S. Department of Defense (W81XWH-12-1-0414)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords: mRNA vaccines, lipopolyplexes, poly(β-amino ester), core-shell nanoparticles, dendritic cells, macropinocytosis, interferon-beta, IL-12, antigen presentation, lung metastasis, B16-OVA tumor, antitumor immunity, vaccine adjuvants, lipid shell
MeSH terms: Animals, Drug Synergism, Female, Liposomes, Male, Mice, Inbred C57BL, Neoplasms, Experimental, RNA, Messenger, Transfection, Treatment Outcome, Cancer Vaccines, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks